Results 81 to 90 of about 436,688 (335)

High-grade Fetal Adenocarcinoma of the Lung: A Case Report

Chinese Journal of Lung Cancer, 2019
Fetal adenocarcinoma of the lung (FLAC) is an extremely rare subtype of lung cancer, accounting for only 0.1% to 0.5% of primary pulmonary malignancy.
Chuan HUANG, Chao MA, Qingjun WU, Zheng WANG, Yaoguang SUN, Peng JIAO, Wenxin TIAN, Hanbo YU, Hongfeng TONG   +8 more
doaj   +1 more source

Long noncoding RNA LINC00673-v4 promotes aggressiveness of lung adenocarcinoma via activating WNT/β-catenin signaling

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance This study uncovers a long noncoding RNA (lncRNA)-mediated mechanism underlying lung adenocarcinoma (LAD) metastasis. We here report that lncRNA LINC00673-v4 expression is up-regulated in LAD and is associated with disease progression.
H. Guan, T. Zhu, Shanshan Wu, Shihua Liu, Bangdong Liu, Jueheng Wu, Junchao Cai, Xun Zhu, Xin Zhang, M. Zeng, Jun Li, E. Song, Mengfeng Li   +12 more
semanticscholar   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

An endothelial growth factor receptor compound mutation of T790M substitution with exon 19 deletion in a previously untreated patient: a case report

Journal of Medical Case Reports, 2019
Background Endothelial growth factor receptor (EGFR) mutations are an essential driver of personalized therapy for patients with lung cancer and are detected in approximately 15% of Caucasian and 50% of Asian patients.
Juan C. Falla-Martinez, Daniela Espinosa, Juan C. Baena, Lisa X. Rodriguez, Luz F. Sua, Angela R. Zambrano   +5 more
doaj   +1 more source

Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation

Proceedings of the National Academy of Sciences of the United States of America, 2019
Significance T cell-targeted therapies are effective against lung cancer only in a fraction of patients, highlighting a need for complimentary approaches.
L. Schmidt, Banu Eskiocak, Ryan Kohn, Celeste Dang, Nikhil S. Joshi, Michel DuPage, Da-Yae Lee, T. Jacks   +7 more
semanticscholar   +1 more source

Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. [PDF]

, 2020
Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy is limited to certain tumors and would benefit from identifying a biomarker predictive of therapeutic response.
Boichard, Amélie, Kurzrock, Razelle, Li, Alex M   +2 more
core  

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

PRC1 contributes to tumorigenesis of lung adenocarcinoma in association with the Wnt/β-catenin signaling pathway

Molecular Cancer, 2017
Background Protein regulator of cytokinesis-1 (PRC1) belongs to the microtubule-associated proteins (MAPs) family, and is involved in cytokinesis.
Ping Zhan, Bin Zhang, Guang-min Xi, Ying Wu, Hong-bing Liu, Ya-fang Liu, Wu-jian Xu, Qing-qing Zhu, Feng Cai, Ze-jun Zhou, Ying-ying Miu, Xiao-xia Wang, Jia-jia Jin, Qian Li, Li-ping Qian, Tang-feng Lv, Yong Song   +16 more
doaj   +1 more source

Squamous Cell Transformation of Primary Lung Adenocarcinoma in a Patient With EML4-ALK Fusion Variant 5 Refractory to ALK Inhibitors.

The Journal of the National Comprehensive Cancer Network, 2019
Histologic transformation from adenocarcinoma to squamous cell carcinoma in lung cancer has not been reported as a mechanism of resistance to ALK inhibition.
J. Gong, J. Gregg, Weijie Ma, K. Yoneda, E. Moore, M. Daly, Yanhong Zhang, M. J. Williams, Tianhong Li   +8 more
semanticscholar   +1 more source